Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.

Related Keywords

Houston ,Texas ,United States ,America ,American ,Vincerx Pharma ,Acerta Pharma ,Pepromene Bio ,Michael Wang ,Biopharma Cayman ,Ideology Health ,Life Sciences ,Oncologist Network ,University Of Texas Md Anderson Cancer Center ,Leukemia Lymphoma Society ,Genentech ,Amphista Therapeutics ,Moffitt Cancer Center ,Bristol Myers Squibb ,Department Of Lymphoma Myeloma ,Practice Point Communications ,Milken Institute ,Eastern Virginia Medical School ,Deciphera Pharmaceuticals ,International Conference On Malignant Lymphoma ,Oncology Specialty Group ,Astrazeneca ,Annual International Conference ,Cancer Center ,Amphista Therapeutics Limited ,Kite Pharma ,Lymphoma Society ,Miltenyi Biomedicine ,Oncternal Therapeutics ,Bantam Pharmaceutical ,Chinese American Hematologist ,Meeting Minds Experts ,Nurix Therapeutics ,Physician Education Resource ,Juno Therapeutics ,Loxo Oncology ,Molecular Templates ,